Key points are not available for this paper at this time.
, suggesting that a different mechanism of action is engaged. These findings support the potential of this dual-targeting approach through a dual-targeting SMDC as a promising therapeutic strategy against high-grade glioma overexpressing the α5β1 integrin receptor.
Arrigoni et al. (Mon,) studied this question.